

***IN VITRO* EVALUATION OF METABOLIC DRUG–DRUG INTERACTIONS: SCIENTIFIC CONCEPTS AND PRACTICAL CONSIDERATIONS**

ALBERT P. LI

In Vitro ADMET Laboratories Inc., Columbia, Maryland

Contents

- 1 Introduction
- 2 Mechanisms of Adverse Drug–Drug Interactions
- 3 Drug Metabolism
- 4 CYP Isoforms
- 5 Human *In Vitro* Experimental Systems for Drug Metabolism
 - 5.1 Hepatocytes
 - 5.2 Liver Postmitochondrial Supernatant (PMS)
 - 5.3 Human Liver Microsomes
 - 5.4 Recombinant P450 Isoforms (rCYP)
 - 5.5 Cytosol
- 6 Mechanisms of Metabolic Drug–Drug Interactions
- 7 Mechanism-Based Approach for the Evaluation of Drug–Drug Interaction Potential
- 8 Experimental Approaches for the *In Vitro* Evaluation of Drug–Drug Interaction Potential
 - 8.1 Study 1: Metabolic Phenotyping 1—Metabolite Identification
 - 8.2 Study 2: Metabolic Phenotyping 2—Identification of Major Metabolic Pathways
 - 8.3 Study 3: Metabolic Phenotyping 3—Identification of P450 Isoform Pathways (P450 Phenotyping)
 - 8.4 Study 4: CYP Inhibitory Potential